Alzheimer's disease drug development pipeline: 2021.
Alzheimer's disease drug development pipeline: 2021.
复制标题
DOI：
10.1002/trc2.12179
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Taghva K
中科院分区：
文献类型：
--
作者：
Cummings J;Lee G;Zhong K;Fonseca J;Taghva K
全世界患有阿尔茨海默病 (AD) 的人数正在快速增长。迫切需要新的治疗方法。我们回顾了当前治疗 AD 临床试验的药物管线。我们询问了临床试验联邦登记处 ClinicalTrials.gov，以确定试验中的药物。 152 项试验中有 126 种药物正在评估 AD 新疗法：3 期试验中有 28 种疗法，2 期试验有 74 种，1 期试验有 24 种。试验中的大多数药物 (82.5%) 以 AD 的潜在生物学为目标，目的是改善疾病； 10.3% 是公认的认知增强剂； 7.1% 是正在开发的用于减轻神经精神症状的药物。该管道分析表明，目标生物过程更加多样化，生物标志物的使用更加频繁，并且正在探索重新利用的药物以确定其治疗 AD 的效用。
The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD. We interrogated ClinicalTrials.gov, the federal registry of clinical trials to identify drugs in trials. There are 126 agents in 152 trials assessing new therapies for AD: 28 treatments in Phase 3 trials, 74 in Phase 2, and 24 in Phase 1. The majority of drugs in trials (82.5%) target the underlying biology of AD with the intent of disease modification; 10.3% are putative cognitive enhancing agents; and 7.1% are drugs being developed to reduce neuropsychiatric symptoms. This pipeline analysis shows that target biological processes are more diversified, biomarkers are more regularly used, and repurposed agents are being explored to determine their utility for the treatment of AD.